The original pump for chemosat was it was so beneficial that demand from end user customers would be sufficient to the cause.
I think actual patients and doctors should be similar across borders. If I had sufficient money, I might be up to 8 to 10 treatments by now if it seemed effective.
So Europe is a mystery, are the individuals in Great Britain mostly too poor to do adequate number of treatments for instance.
On Delcath’s 500th Commercial CHEMOSAT Treatment in Europe:
This is a meaningful milestone for Delcath, one that speaks to the belief physicians in Europe have developed in our product and this therapy for certain types of liver cancers. Our commercialization efforts in Europe have established a considerable body of published and presented research data that demonstrates the safety and efficacy of this therapy in appropriate patients. Further, Dutch Health Authorities recently included CHEMOSAT treatment in their published guidelines for ocular melanoma liver metastases, a step toward potential reimbursement coverage of CHEMOSAT in the Dutch market. We continue to leverage this experience to validate the safety and efficacy of the melphalan/Hepatic Delivery System (CHEMOSAT) in our clinical trials.”
News 
Market Data 
Discover 
